Morocco Market-Entry Roadmap: Seven Nodes from Declaration to Certificate

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The standard path for a Chinese manufacturer entering Morocco runs through seven nodes: selecting a Moroccan licensed establishment → establishment declaration (Article 7) → the 90-day deemed-acceptance window (Article 8) → product classification (Article 4) → dossier compilation (Article 14) → submission and fee payment → issuance of the registration certificate after review by the advisory committee (Articles 12 and 36). The statutory review period runs from submission of a complete dossier and lasts 120 days, and the registration certificate is valid for 5 years. Two numbers frame the whole calendar: the declaration window is measured in weeks and can overlap with dossier preparation, while the review period is measured in months and cannot start until the dossier is genuinely complete. The first node — choosing who will hold the certificate — determines the signatory of every subsequent document in the project, which is why it should be resolved before any technical writing begins rather than after. Sequencing the holder decision first, and the paperwork second, is the single cheapest schedule decision available on this roadmap.

2. Legal basis

Three instruments carry the seven-node roadmap. The law establishes the obligations and the actors; the decree sets the review period and the certificate validity; the ministerial order governs the signing formalities of the administrative documents.

InstrumentReferencePublication dateProvisions
Medical Devices Law (Loi n° 84-12)Dahir n° 1-13-90August 30, 2013Articles 4, 7, 8, 12, 14 and 36
Implementing decree of Law 84-12 (Décret n° 2-14-607)Décret n° 2-14-607September 18, 2014Article 4 (120-day review period); Article 6 (5-year validity)
Ministerial order on registration and placing on the marketArrêté n° 2855-15August 4, 2015Article 3 (signature of the administrative documents)

3. Expert insights

Insight 1: The first node is a question of legal capacity, not of paperwork. Article 12, second paragraph, provides that the registration certificate is issued on application to a manufacturing establishment or importing establishment of medical devices that has been duly declared under Article 7. A foreign manufacturer is simply not among the entities eligible to receive the certificate. This means that finding a company willing to sign and finding a legally licensed establishment able to file are two different matters; only the latter has standing to submit. The distinction sounds obvious, yet a recurring project failure is spending months preparing documentation for a partner whose declaration status or activity scope does not actually qualify it as the filer, discovering the gap only at submission.

Insight 2: The 90-day window in Article 8 is a design the company can use proactively. Within a maximum of 90 days from the submission of the establishment declaration, the authority may request additional information, inspect the premises and issue observations; if it does not respond within that period, silence is deemed acceptance. The clause gives the company a predictable starting point for operations, but deemed acceptance does not exempt the establishment from the periodic inspections provided for in Article 38. Treat the 90 days as a schedulable milestone with a definite endpoint, not as an indefinite waiting period.

Insight 3: The signature sits on the Moroccan side. Article 3 of Arrêté n° 2855-15 requires that all administrative documents in the registration dossier, together with the declaration of conformity to the essential requirements made by the establishment, be dated, signed and stamped by the legal representative of the Moroccan establishment. The checklist additionally requires each document to be signed individually rather than sealed across the whole bound volume with a single cross-page stamp. However complete the foreign manufacturer’s package is, the final production step always happens at the licensed establishment, so the availability, travel schedule and signing throughput of that one person belong on the project plan.

Insight 4: The 120 days is a ceiling, not a promise. Article 4 of Décret n° 2-14-607 sets the review period as an upper limit running from submission of a complete dossier. Time consumed by corrections due to an incomplete dossier does not count against the period, so total elapsed time in practice depends chiefly on the quality of the first submission. A complete, checklist-verified first filing is the cheapest acceleration available.

4. Practical recommendations

  1. Fix the certificate holder and the signatory before the document list. Confirm with the candidate establishment the identity of the legal representative, the appointment resolution, and the realistic signing capacity, and record all three in the cooperation agreement.
  2. Run the establishment declaration and the product dossier in parallel. The 90-day window of Article 8 can overlap with dossier compilation; there is no need to serialize the two workstreams and pay for the dead time.
  3. Build to the complete-dossier standard in one pass. Treat a first-round correction request as a project risk: verify the package line by line against the current AMMPS checklist before submission, not after.
  4. Budget time in two segments. Plan on 90 days for the establishment declaration plus 120 days for dossier review, and add preparation and translation time; for a median project, a schedule of 6 to 12 months is prudent (practical estimate: this range is GRZAN’s scheduling recommendation based on the statutory time limits and consistent agency practice; it is not an official commitment).
  5. Change partners through Article 17, not through paperwork goodwill. A change of licensed establishment requires a transfer authorization; it is not a contact-detail update (see the dedicated article in this series).

5. Verification checklist

  • □ A Moroccan licensed establishment has been selected and has confirmed that it completed the declaration under Article 7
  • □ The declared activity types of the licensed establishment cover import
  • □ The legal representative has been identified and the signing and stamping workflow confirmed
  • □ The version of the establishment declaration checklist has been recorded (currently DE RD-IS-PS/04)
  • □ The product class has been determined under Article 4 and documented
  • □ The dossier has been self-checked item by item against the current AMMPS checklist (DE ER DM/01)
  • □ The project plan reflects the 120-day review period and the 5-year certificate validity
  • □ A correction buffer and milestone review points have been reserved in the schedule

Regulatory information verified as of October 30, 2026. GRZAN guides manufacturers through the full Moroccan market-entry roadmap, from licensed-establishment selection and declaration to dossier preparation, submission and certificate issuance before AMMPS. For project inquiries, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail